CUMBERLAND PHARMACEUTICALS INC
CPIX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CPIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CPIX
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing therapies for rare diseases and other serious conditions, with a portfolio of FDA-approved brands and a clinical pipeline centered on ifetroban.
Key risk: Cash burn and liquidity risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$126.8M
Cash Runway
9.9 moLead Asset
Dyscorban® (Phase 2)Next Catalyst
Patent_Expiry · Jan 1, 2027Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials · 3 catalysts · 2 FDA decisions for CUMBERLAND PHARMACEUTICALS INC.
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing therapies for rare diseases and other serious conditions, with a portfolio of FDA-approved brands and a clinical pipeline centered on ifetroban.
- Cumberland is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions [sec_mda · as of 2026-08-07].
- As of June 30, 2026, the company reported cash and cash equivalents of $3.9M, total revenue of $0.2M, and a net loss of -$4.3M [sec].
- The company has a strategic focus on advancing its ifetroban development programs, including a Duchenne muscular dystrophy study with breakthrough top-line results [sec_mda · as of 2026-03-09].
- Cumberland selectively adds complementary FDA-approved brands, such as Talicia® for H. pylori infection, to diversify its marketed product portfolio [sec_mda · as of 2026-03-09].
- The company believes its cash and cash equivalents are sufficient to fund operations and product development for at least twelve months following June 30, 2026 [sec_mda · as of 2026-08-07].
What works
- Cumberland has a diversified portfolio of FDA-approved brands (e.g., Acetadote, Caldolor, Vibativ, Sancuso, Talicia) that generate revenue and provide a foundation for growth [sec_mda · as of 2026-03-09].
- The company has a promising clinical pipeline, particularly ifetroban for Duchenne muscular dystrophy, which has shown breakthrough results and is progressing toward FDA meetings [sec_mda · as of 2026-03-09].
- Cumberland employs a capital-efficient strategy of acquiring under-promoted, FDA-approved drugs and late-stage development candidates, reducing R&D risk [sec_mda · as of 2026-05-08].
- The company has established partnerships with academic institutions and industry partners to advance clinical programs and expand research efforts [sec_mda · as of 2026-08-07].
What to weigh
- Cumberland reported a net loss of -$4.3M for the six months ended June 30, 2026, and has negative working capital of -$1.55M as of that date [sec] [sec_mda · as of 2026-08-07].
- The company's cash and cash equivalents declined from $11.4M at December 31, 2025 to $3.9M at June 30, 2026, indicating a significant cash burn rate [sec_mda · as of 2026-08-07].
- Cumberland's reliance on a small number of marketed products and its dependence on the success of its pipeline (e.g., ifetroban) exposes it to concentration risk [sec_mda · as of 2026-03-09].
- The company faces risks inherent in clinical development and regulatory review, including potential delays or failures in advancing ifetroban and other candidates [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Cumberland is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions.
“Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us," or "our"), is an innovation-focused biopharmaceutical company developing new product candidates for rare diseases and other serious conditions.”
SEC MD&A · August 7, 2026
Cumberland has a strategic focus on advancing its ifetroban development programs, including a Duchenne muscular dystrophy study with breakthrough top-line results.
“Progressed our clinical development programs for ifetroban announcing breakthrough top-line study results from our Duchenne muscular dystrophy (DMD) study and presented them at two national DMD conferences.”
SEC MD&A · March 9, 2026
The company selectively adds complementary FDA-approved brands, such as Talicia® for H. pylori infection.
“Expanded our commercial portfolio adding Talicia ® , an FDA-approved therapy for the treatment of Helicobacter pylori infection, strengthening our gastroenterology franchise and further diversifying our base of marketed products.”
SEC MD&A · March 9, 2026
Catalyst timeline
- 2027-01-01 · Patent_Expiry · VIBATIV — Patent/exclusivity expiry for VIBATIV could impact revenue from this brand.
- 2032-03-16 · Patent_Expiry · CALDOLOR — Patent/exclusivity expiry for CALDOLOR may affect long-term revenue.
- 2032-04-06 · Patent_Expiry · ACETADOTE — Patent/exclusivity expiry for ACETADOTE could influence future earnings.
Risks & what to watch (4)›
Key risks
- Cash burn and liquidity risk — Cash declined from $11.4M (Dec 2025) to $3.9M (Jun 2026); net loss of -$4.3M; negative working capital of -$1.55M [sec] [sec_mda · as of 2026-08-07].
- Clinical and regulatory risk — Pipeline success depends on ifetroban and other candidates; clinical development and regulatory review involve inherent risks of delay or failure [sec_mda · as of 2026-08-07].
- Concentration risk — Reliance on a small number of marketed products and pipeline candidates; any setback could materially impact operations [sec_mda · as of 2026-03-09].
- Macroeconomic and market risks — Factors such as interest rates, inflation, tariffs, and competition could affect operations and financial results [news · published 2026-08-28].
What to watch
- FDA meeting and next steps for ifetroban in Duchenne muscular dystrophy following breakthrough results [sec_mda · as of 2026-03-09].
- Cash runway and ability to secure additional financing given declining cash reserves [sec_mda · as of 2026-08-07].
- Progress of ongoing Phase 2 clinical trials for ifetroban in other indications (e.g., NCT05571059) [catalyst].
- Potential acquisition of additional FDA-approved brands or late-stage candidates to expand the portfolio [sec_mda · as of 2026-05-08].
Sources: Catalysts · News · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CUMBERLAND PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CUMBERLAND PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
9.9 months
D/E 2.62 · 0% dilution
Lead: Approved
6 candidates
3 upcoming, next in ~124d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$9.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 723,518 | $2.4M |
| renaissance technologies llc | 470,696 | $1.5M |
| perceptive advisors llc | 393,956 | $1.3M |
| dimensional fund advisors lp | 276,359 | $898K |
| bridgeway capital management, llc | 163,468 | $531K |
| boothbay fund management, llc | 127,694 | $415K |
| geode capital management, llc | 114,293 | $371K |
| j. goldman & co lp | 81,040 | $263K |
| susquehanna international group, llp | 73,500 | $239K |
| jane street group, llc | 58,907 | $191K |
Showing top 10 of 29 institutional holders of CUMBERLAND PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.0%
- Days to cover
- 0.2
- Shares short
- 523,399
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CPIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for CUMBERLAND PHARMACEUTICALS INC?
Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing therapies for rare diseases and other serious conditions, with a portfolio of FDA-approved brands and a clinical pipeline centered on ifetroban.
What is CUMBERLAND PHARMACEUTICALS INC's lead drug candidate?
CUMBERLAND PHARMACEUTICALS INC's most advanced tracked candidate is Dyscorban® (Phase 2) for cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
What is CUMBERLAND PHARMACEUTICALS INC's next catalyst?
CUMBERLAND PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VIBATIV" — expected January 1, 2027.
Who is the CEO of CUMBERLAND PHARMACEUTICALS INC?
Mr. A. J. Kazimi MBA is the chief executive officer of CUMBERLAND PHARMACEUTICALS INC (CPIX).
Where is CUMBERLAND PHARMACEUTICALS INC headquartered?
CUMBERLAND PHARMACEUTICALS INC (CPIX) is headquartered in Nashville, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.